Background: A "hybrid" strategy selectively uses adenosine to measure FFR only in lesions with an intermediate resting index (iFR or resting Pd/Pa). It trades off diagnostic accuracy against a reduced need for vasodilator administration. The ADVISE II and SYNTAX II studies employ such an approach. However, its effect on treatment decisions for coronary revascularization remains unclear compared to the evidencebased strategy of FFR for all lesions. These tradeoffs are important when contemplating future outcomes trials testing a hybrid strategy. Methods: The international, multicenter RESOLVE study applied the official Volcano iFR software algorithm in a blinded core lab. Hybrid strategies for both iFR (measure FFR only if iFR¼0.86-0.93) and resting Pd/Pa (measure FFR only if Pd/ Pa¼0.89-0.94) were applied. Based on DEFER, FAME and FAME 2, FFR>0.80 served as an unequivocal standard for no ischemia, FFR 0.75 served as an unequivocal standard for ischemia, and FFR 0.76-0.80 was intermediate. Conclusions: Future outcomes trials could compare a hybrid strategy to universal FFR. RESOLVE suggests that resting Pd/Pa will perform at least as well as iFR for this purpose. Given the z90-95% agreement with FFR, such trials could expect to enroll only 2 clearly misclassified lesions (for FFR 0.80, falling to 1 lesion when including gray-zone FFR¼0.76-0.80) for every 20 screened.
Conclusions: Future outcomes trials could compare a hybrid strategy to universal FFR. RESOLVE suggests that resting Pd/Pa will perform at least as well as iFR for this purpose. Given the z90-95% agreement with FFR, such trials could expect to enroll only 2 clearly misclassified lesions (for FFR 0.80, falling to 1 lesion when including gray-zone FFR¼0.76-0.80) for every 20 screened. Background: The extremes of discordance between fractional flow reserve(FFR) and coronary flow velocity reserve(CFVR) (e.g. normal FFR with abnormal CFVR versus abnormal FFR with normal CFVR) are suggested to originate from diverging distributions of epicardial and microvascular disease. In contrast, the origin of discordance of CFVR with FFR within vessels with normal FFR and within vessel with abnormal FFR has not been elucidated, which is typically of more pertinence in clinical practice. We aimed to determine the physiological characteristics that delineate discordance of CFVR with FFR in FFR-positive, as well as in FFR-negative stenoses. Methods: 157 coronary stenoses were studied using intracoronary pressure and flow velocity measurements. We calculated FFR, CFVR, hyperemic stenosis resistance index (HSR), as well as basal (BMR) and hyperemic (HMR) microvascular resistance index. FFR 0.75, and CFVR<2.0 was considered abnormal. Results: When FFR<0.75, CFVR<2.0 resulted from a high baseline flow velocity as a consequence of a low BMR (Table, left panel) . Similarly, when FFR!0.75, CFVR<2.0 occurred from a high baseline flow velocity, corresponding to a low BMR (Table, Right panel). The two groups in which FFR and CFVR were discordant, were characterized by divergent distributions of epicardial and microvascular resistances.
Conclusions:
The magnitude of basal microvascular resistance is the major determinant of discordance of CFVR with FFR within vessels with a normal FFR, as well as within vessels with an abnormal FFR. This finding suggests that microvascular abnormalities are the root cause of discordance of CFVR with FFR in patients with a comparable degree of epicardial disease as identified by FFR, which may have important implications for pressure-only stenosis evaluation. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM www.jacctctabstracts2013.com
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